Mescaline for AUD

Journey Collab plan to assess the use of mescaline for treating alcohol use disorder (AUD) in the clinical trial process.

The first human trial will begin in 2022.

Topic Addiction Alcohol Use Disorder
Compound Mescaline
Country United States of America
Visit trial
Status Planned
Results Published No
Start date 14 March 2022
End date 31 January 2024
Chance of happening 69%
Phase Not Applicable
Design Open
Type Interventional
Generation First
Participants 15
Sex All
Age 18- 99
Therapy No

Trial Details



NCT Number

Sponsors & Collaborators

Journey Colab
Journey Colab aims to develop a portfolio of psychedelic compounds for use in therapy, the first of which is (synthetic) mescaline. The company puts a strong focus on collaborating with non-profits, Indigenous groups, and clinicians.

Data attribution

A large set of the trials in our database are sourced from ClinicalTrials.gov (CTG). We have modified these post to display the information in a more clear format or to correct spelling mistakes. Our database in actively updated and may show a different status (e.g. completed) if we have knowledge of this update (e.g. a published paper on the study) which isn't reflected yet on CTG. If a trial is not sourced from CTG, this is indicated on this page and you can follow the link to the alternative source of information.